Zomagen Biosciences Ltd.

This study tested whether the drug VTX3232 is safe for people with early-stage Parkinson's disease. Eleven participants took the drug for 28 days and were monitored for side effects. The goal was to check safety and how the drug moves through the body, not to cure the disease.

This study tested an experimental drug called VTX3232, given alone or with the weight-loss drug semaglutide, in 176 adults with obesity. The main goal was to check safety and side effects over 12 weeks. Researchers also measured changes in inflammation levels. The trial is comple…